Summary:

Lupin Limited has expanded its line of generics by introducing Dapagliflozin and Metformin Hydrochloride extended-release tablets, two generic anti-diabetic medications, in the US. The medication, which targets glycaemic management in people with type 2 diabetes and is comparable to Xigduo XR, was approved by the USFDA via the ANDA procedure. It offers a variety of therapeutic alternatives because to its varied dosage levels.

Lupin's position in the US generic market is strengthened by the launch, particularly in the treatment of diabetes. By lowering the frequency of doses, the extended-release formulation improves patient compliance. With a diverse worldwide portfolio, Lupin continues to increase access to reasonably priced medications by taking advantage of regulatory approvals and rising demand for the treatment of chronic illnesses.

Source: IBEF

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.